• 【利伐沙班和达比加群对人主动脉狭窄瓣膜内凝血和炎症因子局部表达的影响。】 复制标题 收藏 收藏
    DOI:10.1016/j.vph.2020.106679 复制DOI
    作者列表:Wypasek E,Natorska J,Mazur P,Kopytek M,Gawęda B,Kapusta P,Madeja J,Iwaniec T,Kapelak B,Undas A
    BACKGROUND & AIMS: BACKGROUND:Treatment with non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran (a direct thrombin inhibitor) or rivaroxaban (a direct inhibitor of factor [F] Xa) attenuates atherosclerotic plaque progression in hypercholesterolemic mice. PURPOSE:To evaluate the effect of NOACs application on the expression of coagulation proteins in loco within stenotic aortic valves and in valve interstitial cells (VICs) from patients with severe aortic stenosis (AS). METHODS:Primary cultures of VICs obtained from 90 patients undergoing aortic valve replacement were stimulated with TNF-α (50 ng/mL) and pre-treated with rivaroxaban (1 and 10 ng/mL) or dabigatran (25 and 250 ng/mL). The expression of coagulation proteins was analyzed by immunofluorescence. Cytokine levels were measured by ELISA. RESULTS:FX, FXa, FVII, thrombin and PAR1/2 were present in loco within human aortic stenotic valves. Cultured VICs exhibited constant expression of FX, TF, PAR1/2. Exposure of VICs to TNF-α caused the upregulated expression of TF, PAR1/2 and induced expression of thrombin, FVII and FXa. FX was expressed by 80% of VICs, regardless of stimulation. Cultured VICs were able to synthesize metalloproteinases 1-3, IL-6, IL-32, IL-34, osteopontin and osteocalcin, the levels of which increased under TNF-α stimulation. NOACs added to culture inhibited coagulation factor and PAR1/2 expression. Moreover, NOACs down-regulated VIC-derived proteins responsible for valve calcification and extracellular matrix remodeling. CONCLUSIONS:NOACs at therapeutic concentrations may inhibit the effects of FXa and thrombin at in vitro level. It might be speculated that long-term treatment with rivaroxaban or dabigatran could attenuate the progression of AS in humans.
    背景与目标:
  • 【短暂性脑缺血发作和轻度缺血性中风后的早期达比加群治疗不会导致出血性转化。】 复制标题 收藏 收藏
    DOI:10.1017/cjn.2020.84 复制DOI
    作者列表:Alrohimi A,Ng K,Dowlatshahi D,Buck B,Stotts G,Thirunavukkarasu S,Shamy M,Kalashyan H,Sivakumar L,Shuaib A,Sharma M,Butcher K
    BACKGROUND & AIMS: OBJECTIVES:The optimal timing of anticoagulation after ischemic stroke in atrial fibrillation (AF) patients is unknown. Our aim was to demonstrate the feasibility and safety of initiating dabigatran therapy within 14 days of transient ischemic attack (TIA) or minor stroke in AF patients. PATIENTS AND METHODS:A prospective, multi-center registry (NCT02415855) in patients with AF treated with dabigatran within 14 days of acute ischemic stroke/TIA (National Institutes of Health Stroke Scale (NIHSS) ≤ 3) onset. Baseline and follow-up computed tomography (CT) scans were assessed for hemorrhagic transformation (HT) and graded by using European Cooperative Acute Stroke Study criteria. RESULTS:One hundred and one patients, with a mean age of 72.4 ± 11.5 years, were enrolled. Median infarct volume was 0 ml. Median time from index event onset to dabigatran initiation was 2 days, and median baseline NIHSS was 1. Pre-treatment HT was present in seven patients. No patients developed symptomatic HT. On the day 7 CT scan, HT was present in six patients (one progressing from baseline hemorrhagic infarction type 1). Infarct volume was a predictor of incident HT (odds ratio = 1.063 [1.020-1.107], p < 0.003). All six (100%) patients with new/progressive HT were functionally independent (modified Rankin Scale (mRS) = 0-2) at 30 days, which was similar to those without HT (90%, p = 0.422). Recurrent ischemic events occurred within 30 days in four patients, two of which were associated with severe disability and death (mRS 5 and 6, respectively). CONCLUSION:Early dabigatran treatment did not precipitate symptomatic HT after minor stroke. Asymptomatic HT was associated with larger baseline infarct volumes. Early recurrent ischemic events may be clinically more important.
    背景与目标:
  • 【与成人相比,达比加群在儿科患者中的抗凝作用: 来自三项儿科临床试验的综合数据。】 复制标题 收藏 收藏
    DOI:10.1055/s-0038-1668132 复制DOI
    作者列表:Maas H,Gropper S,Huang F,Stangier J,Tartakovsky I,Brueckmann M,Halton JML,Mitchell LG
    BACKGROUND & AIMS: BACKGROUND: Physiological age-related changes in the haemostatic and coagulation systems result in differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated the response of anticoagulant assays to dabigatran etexilate (DE) in children compared with adults. OBJECTIVE: This article assesses the relationship between plasma dabigatran concentration and coagulation assay results across age groups in children and adults. PATIENTS AND METHODS: Data from three clinical trials in which children received DE following standard of care for venous thromboembolism were compared with data from adult clinical trials. The effects of dabigatran concentration on diluted thrombin time (dTT), ecarin clotting time (ECT) and activated partial thromboplastin time (aPTT) were analysed graphically and with modelling. RESULTS: The concentration-dTT relationships were consistent in children across all ages and adults in the graphical analysis. For ECT and aPTT, relationships based on ratios over baseline were similar across all ages; absolute clotting times showed that the same exposure resulted in longer clotting times in some of the children aged < 1 year versus adults. Modelling showed concentration-clotting time relationships for all three assays were largely comparable between adults and children, except in those aged < 2 months, in whom there was a slight upward shift in ECT and aPTT relative to adults. CONCLUSION: Results suggest that developmental haemostatic changes will have little impact on response to DE. However, further paediatric clinical trials assessing the relationship between coagulation assay responses and clinical outcomes will be needed to confirm this finding.
    背景与目标:
  • 【连续华法林与围手术期达比加群相比,可减少因房颤或左心房扑动而进行导管消融的患者的中风和全身性栓塞。】 复制标题 收藏 收藏
    DOI:10.1007/s10840-013-9793-7 复制DOI
    作者列表:Kaiser DW,Streur MM,Nagarakanti R,Whalen SP,Ellis CR
    BACKGROUND & AIMS: PURPOSE:Left atrial catheter ablation for patients with atrial fibrillation (AF) requires periprocedural anticoagulation to minimize thromboembolic complications. High rates of major bleeding complications using dabigatran etexilate for periprocedural anticoagulation have been reported, raising concerns regarding its safety during left atrial catheter ablation. We sought to evaluate the safety and efficacy of a dabigatran use strategy versus warfarin, at a single high-volume AF ablation center. METHODS:We performed a retrospective analysis on consecutive patients undergoing left atrial ablation at Vanderbilt Medical Center from January 2011 through August 2012 with a minimum follow-up of 3 months. Patient cohorts were divided into two groups, those utilizing dabigatran etexilate pre- and post-ablation and those undergoing ablation on dose-adjusted warfarin, with or without low-molecular-weight heparin bridging. Dabigatran was held 24-30 h pre-procedure and restarted 4-6 h after hemostasis was achieved. We evaluated all thromboembolic and bleeding complications at 3 months post-ablation. RESULTS:A total of 254 patients underwent left atrial catheter ablation for atrial fibrillation or left atrial flutter. Periprocedural anticoagulation utilized dabigatran in 122 patients and warfarin in 135 patients. Three late thromboembolic complications occurred in the dabigatran group (2.5 %), compared with one (0.7 %) in the warfarin group (p = 0.28). The dabigatran group had similar minor bleeding (2.5 vs. 7.4 %, p = 0.07), major bleeding (1.6 vs. 0.7 %, p = 0.51), and composite of bleeding and thromboembolic complications (6.6 vs. 8.9 %, p = 0.49) when compared to warfarin. There were no acute thromboembolic complications in either group (<24 h post-ablation). CONCLUSIONS:In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin. A prospective randomized study is warranted.
    背景与目标:
  • 【老年患者的达比加群谷浓度。】 复制标题 收藏 收藏
    DOI:10.1136/ejhpharm-2020-002456 复制DOI
    作者列表:Gommans E,Grouls RJE,Kerkhof D,Houterman S,Simmers T,Van der Linden C
    BACKGROUND & AIMS: OBJECTIVES:The aim of this observational study was to explore dabigatran concentrations in elderly and very elderly patients in a real-life population. Patients aged >75 years receiving dabigatran have a significantly higher risk of gastrointestinal bleeding compared withthose receiving warfarin. High trough concentrations have an important impact on this bleeding risk. METHODS:We measured dabigatran trough concentrations in 75 patients with atrial fibrillation, divided into age categories <75, ≥75 to 84 and ≥85 years. The most important exclusion criteria were use of interacting medication and severe renal failure. We analysed absolute trough concentrations and concentrations normalised for dose. RESULTS:Trough concentrations were considerably higher in the highest age category. Dose-normalised medians were 0.66, 0.83 and 1.20 ng/mL/mg in the <75, ≥75-84 and ≥85 age groups, respectively (p=0.004). CONCLUSION:Clinicians should be aware of higher dabigatran concentrations in elderly patients despite dose reduction.
    背景与目标:
  • 【达比加群用于预防房颤中风和全身性栓塞: 一项很好的单一技术评估。】 复制标题 收藏 收藏
    DOI:10.1007/s40273-013-0051-8 复制DOI
    作者列表:Faria R,Spackman E,Burch J,Corbacho B,Todd D,Pepper C,Woolacott N,Palmer S
    BACKGROUND & AIMS: :The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for the clinical and cost-effectiveness of this drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) as part of the NICE single technology appraisal process. The Centre for Reviews and Dissemination and the Centre for Health Economics at the University of York were commissioned to act as the evidence review group (ERG). This article presents a summary of the manufacturer's submission, the ERG report and the subsequent development of NICE guidance for the use of dabigatran within the UK National Health Service. Dabigatran was granted marketing authorisation by the European Medicines Agency for a sequential dosing regimen (DBG sequential), in which patients under 80 years are treated with dabigatran 150 mg twice daily (DBG150) and patients 80 years and over are given dabigatran 110 mg twice daily (DBG110). NICE decisions are bound by the marketing authorisation; therefore, the decision problem faced by the committee was whether the DBG sequential regimen was effective and cost-effective compared with warfarin or aspirin for patients with non-valvular AF and one or more risk factors. The RE-LY trial, a large multi-centre non-inferiority randomised clinical trial, was the primary source of clinical evidence. DBG150 was shown to be non-inferior, and subsequently superior to warfarin, for the primary outcome of all stroke/systemic embolism. DBG110 was found to be non-inferior to warfarin. Results were presented for a post hoc subgroup analysis for patients under and over 80 years of age, where DBG110 showed a statistically significant reduction of haemorrhagic stroke and intracranial haemorrhage in comparison to warfarin in patients over 80 years of age. This post hoc subgroup analysis by age was the basis for the licensed DBG sequential regimen. The economic evaluation compared the costs and outcomes of DBG110, DBG150 and DBG sequential against warfarin, aspirin, and aspirin plus clopidogrel. Across the three dosing regimens, dabigatran was associated with greater costs and better health outcomes than warfarin; however, DBG150 offered the most benefits and dominated DBG110 and DBG sequential (i.e. less costly and more effective). The cost-effectiveness of DBG150 was less favourable for patients well controlled on warfarin. In the first appraisal meeting, the committee issued a 'minded no' decision until additional analyses on the licensed DBG sequential regimen were presented by the manufacturer. These additional analyses indicated that the incremental cost-effectiveness ratio (ICER) of the DBG sequential regimen compared with warfarin ranged from £8,388 to £18,987 per quality-adjusted life year (QALY) gained depending on the level of monitoring costs assumed for warfarin. Patients on warfarin would need to be within therapeutic range 83-85 % of the time for the ICER to exceed £30,000 per additional QALY. Following consideration of the additional evidence and the responses from a large number of consultees and commentators, the committee recommended dabigatran as DBG sequential as an option for the prevention of stroke and systemic embolism in people with non-valvular AF with one or more risk factors for ischaemic stroke.
    背景与目标: : 国家健康和临床卓越研究所 (NICE) 邀请了达比加群酯的制造商 (勃林格殷格翰有限公司,作为NICE单一技术评估过程的一部分,该药物用于预防非瓣膜性房颤 (AF) 患者的中风和全身性栓塞的临床和成本效益的证据。约克大学的审查和传播中心和卫生经济学中心被委托担任证据审查小组 (ERG)。本文介绍了制造商提交的内容,ERG报告以及随后在英国国家卫生局内使用达比加群的NICE指南的开发摘要。达比加群获得了欧洲药品管理局的连续给药方案 (DBG sequential) 的上市许可,其中80岁以下的患者每天两次接受达比加群150 mg治疗 (DBG150),80岁及以上的患者每天两次接受达比加群110 mg治疗 (DBG110)。NICE的决定受营销授权的约束; 因此,委员会面临的决策问题是,对于非瓣膜性房颤和一种或多种危险因素的患者,与华法林或阿司匹林相比,DBG序贯方案是否有效且具有成本效益。RE-LY试验是一项大型的多中心非劣效性随机临床试验,是临床证据的主要来源。在所有卒中/全身性栓塞的主要结局中,DBG150显示非劣于华法林,随后优于华法林。发现DBG110不劣于华法林。结果是针对80岁以下和80岁以上的患者进行的事后亚组分析,其中与80岁以上的患者相比,DBG110显示出血性中风和颅内出血的统计学上显着减少。这项按年龄进行的事后亚组分析是许可的DBG序贯方案的基础。经济评估比较了DBG110,DBG150和DBG顺序对华法林,阿司匹林和阿司匹林加氯吡格雷的成本和结果。在三种给药方案中,达比加群比华法林具有更高的成本和更好的健康结果; 然而,DBG150提供了最大的益处,并且主导了DBG110和DBG顺序 (即成本更低且更有效)。对于华法林控制良好的患者,DBG150的成本效益较差。在第一次评估会议上,委员会发布了 “不考虑” 的决定,直到制造商对许可的DBG顺序方案进行了其他分析。这些额外的分析表明,与华法林相比,DBG序贯方案的增量成本效益比 (ICER) 在每个质量调整生命年 (QALY) 获得的8,388英镑至18,987英镑之间,这取决于华法林的监测成本水平。服用华法林的患者需要在83-85% 的治疗范围内,ICER每增加QALY超过30,000英镑。在考虑了其他证据以及大量咨询人员和评论员的回应之后,委员会建议达比加群作为DBG顺序疗法,作为预防具有一种或多种缺血性卒中危险因素的非瓣膜性房颤患者中风和全身性栓塞的一种选择。
  • 【达比加群与华法林与非瓣膜性心房颤动患者骨质疏松性骨折风险之间的关系.】 复制标题 收藏 收藏
    影响因子 :
    发表时间:2017-03-21
    来源期刊:JAMA
    DOI:10.1001/jama.2017.1363 复制DOI
    作者列表:Lau WC,Chan EW,Cheung CL,Sing CW,Man KK,Lip GY,Siu CW,Lam JK,Lee AC,Wong IC
    BACKGROUND & AIMS: Importance:The risk of osteoporotic fracture with dabigatran use in patients with nonvalvular atrial fibrillation (NVAF) is unknown. Objective:To investigate the risk of osteoporotic fracture with dabigatran vs warfarin in patients with NVAF. Design, Setting, and Participants:Retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF from 2010 through 2014 and prescribed dabigatran or warfarin were matched by propensity score at a 1:2 ratio with follow-up until July 31, 2016. Exposures:Dabigatran or warfarin use during the study period. Main Outcomes and Measures:Risk of osteoporotic hip fracture and vertebral fracture was compared between dabigatran and warfarin users using Poisson regression. The corresponding incidence rate ratio (IRR) and absolute risk difference (ARD) with 95% CIs were calculated. Results:Among 51 496 patients newly diagnosed with NVAF, 8152 new users of dabigatran (n = 3268) and warfarin (n = 4884) were matched by propensity score (50% women; mean [SD] age, 74 [11] years). Osteoporotic fracture developed in 104 (1.3%) patients during follow-up (32 dabigatran users [1.0%]; 72 warfarin users [1.5%]). Results of Poisson regression analysis showed that dabigatran use was associated with a significantly lower risk of osteoporotic fracture compared with warfarin (0.7 vs 1.1 per 100 person-years; ARD per 100 person-years, -0.68 [95% CI, -0.38 to -0.86]; IRR, 0.38 [95% CI, 0.22 to 0.66]). The association with lower risk was statistically significant in patients with a history of falls, fractures, or both (dabigatran vs warfarin, 1.6 vs 3.6 per 100 person-years; ARD per 100 person-years, -3.15 [95% CI, -2.40 to -3.45]; IRR, 0.12 [95% CI, 0.04 to 0.33]), but not in those without a history (0.6 vs 0.7 per 100 person-years; ARD per 100 person-years, -0.04 [95% CI, 0.67 to -0.39]; IRR, 0.95 [95% CI, 0.45 to 1.96]) (P value for interaction, <.001). Conclusions and Relevance:Among adults with NVAF receiving anticoagulation, the use of dabigatran compared with warfarin was associated with a lower risk of osteoporotic fracture. Additional study, perhaps including randomized clinical trials, may be warranted to further understand the relationship between use of dabigatran vs warfarin and risk of fracture.
    背景与目标:
  • 【达比加群与华法林治疗急性肺栓塞。对重新覆盖和重新覆盖II的数据进行汇总分析。】 复制标题 收藏 收藏
    DOI:10.1160/TH16-04-0271 复制DOI
    作者列表:Goldhaber SZ,Schellong S,Kakkar A,Eriksson H,Feuring M,Kreuzer J,Fraessdorf M,Schulman S
    BACKGROUND & AIMS: :Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset for the efficacy analysis consisted of 2553 and 2554 patients who were randomised to dabigatran and warfarin, respectively. Recurrent VTE/VTE-related death during the study period and additional 30-day follow-up occurred in 2.7 % of all patients on dabigatran and in 2.4 % on warfarin (hazard ratio [HR] 1.09 [95 % confidence interval 0.77, 1.54]). In patients with PE as their index event, recurrent VTE/VTE-related death occurred in 2.9 % vs 3.1 % of patients (HR 0.93 [0.53, 1.64]). There were significantly fewer major bleeding events in patients treated with dabigatran than with warfarin (HR 0.60 [0.36, 0.99]). The pattern was similar both in patients with PE and in those with DVT alone as the index event. These analyses of the pooled dataset from the RE-COVER and RE-COVER II trials indicate that dabigatran is as effective as warfarin in preventing recurrent VTE, regardless of whether patients present with symptomatic PE (with or without DVT) or with symptomatic DVT alone. Dabigatran was also associated with a lower risk of bleeding than warfarin, regardless of the index event.
    背景与目标: : 在预防复发性静脉血栓栓塞 (VTE) 方面,达比加群不逊于华法林,在两项大规模随机试验 (RE-COVER和RE-COVER II) 中,达比加群的出血率低于华法林。在这项研究中,我们根据符合患者入组条件的指数事件 (有症状的肺栓塞 (PE) 伴或不伴深静脉血栓形成 (DVT) 或单独DVT),研究达比加群与华法林的疗效和安全性。然后,我们分析达比加群与华法林对PE患者的抗凝作用。用于疗效分析的汇总数据集由2553和2554名患者组成,他们分别被随机分配到达比加群和华法林。在研究期间和额外的30天随访期间,达比加群所有患者的2.7   % 和华法林的2.4   % 发生了VTE/VTE相关的复发性死亡 (风险比 [HR] 1.09 [95  % 置信区间0.77,1.54])。以PE为指标事件的患者中,2.9   % 比3.1   % 的患者发生VTE/VTE相关的复发性死亡 (HR 0.93 [0.53,1.64])。与华法林相比,达比加群治疗的患者的主要出血事件显著减少 (HR 0.60 [0.36,0.99])。PE患者和单纯DVT患者的模式相似。这些来自RE-COVER和RE-COVER II试验的汇总数据集的分析表明,无论患者是否出现有症状的PE (有或没有DVT) 或单独有症状的DVT,达比加群在预防复发性VTE方面与华法林一样有效。无论指数事件如何,达比加群的出血风险也低于华法林。
  • 【达比加群、利伐沙班和华法林预防中国房颤患者卒中的成本-效果分析。】 复制标题 收藏 收藏
    DOI:10.1186/s12913-021-06084-1 复制DOI
    作者列表:Wei H,Cui C,Cui X,Liu Y,Li D
    BACKGROUND & AIMS: BACKGROUND AND OBJECTIVE:To evaluate the cost-effectiveness of new anticoagulants and warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). METHODS:The Markov model was constructed to compare patients' quality-adjusted life-years (QALYs) using drug cost, the cost of the examination after taking a drug, and the incremental cost of other treatments. Both dabigatran (110 and 150 mg, twice a day) and rivaroxaban (20 mg, once a day) were compared with warfarin (3-6 mg, once a day). Willingness to pay, three times the 2018 China GDP per capita (9481.88 $), was the cost-effect threshold in our study. RESULTS:The total cost were was 5317.31$, 29673.33$, 23615.49$, and 34324.91$ for warfarin, rivaroxaban, dabigatran 110 mg bid, and dabigatran 150 mg bid, respectively. The QALYs for each of the four interventions were 11.07 years, 15.46 years, 12.4 years, and 15 years, respectively. The cost-effectiveness analysis of the three new oral anticoagulants and warfarin showed that the incremental cost-effectiveness ratio (ICER) was 5548.07$/QALY when rivaroxaban was compared with warfarin. Rivaroxaban was the most cost-effective choice and warfarin was the least. CONCLUSIONS:In Chinese patients with AF, although warfarin is cheaper, rivaroxaban has a better cost-effectiveness advantage from an economic point of view.
    背景与目标:
  • 【在接受Ixekizumab治疗的银屑病患者中,与达比加群相关的急性泛发性脓疱病 (AGEP) 及其发病机制。】 复制标题 收藏 收藏
    DOI:10.1111/dth.13018 复制DOI
    作者列表:Schrom K,Pacifico A,Conic RRZ,Pigatto PDM,Malagoli P,Morrone A,Finelli R,Bragazzi NL,Damiani G
    BACKGROUND & AIMS: -2
    背景与目标: -2
  • 【用达比加群或利伐沙班治疗非瓣膜性房颤的老年医疗保险受益人的中风、出血和死亡风险.】 复制标题 收藏 收藏
    DOI:10.1001/jamainternmed.2016.5954 复制DOI
    作者列表:Graham DJ,Reichman ME,Wernecke M,Hsueh YH,Izem R,Southworth MR,Wei Y,Liao J,Goulding MR,Mott K,Chillarige Y,MaCurdy TE,Worrall C,Kelman JA
    BACKGROUND & AIMS: Importance:Dabigatran and rivaroxaban are non-vitamin K oral anticoagulants approved for stroke prevention in patients with nonvalvular atrial fibrillation (AF). There are no randomized head-to-head comparisons of these drugs for stroke, bleeding, or mortality outcomes. Objective:To compare risks of thromboembolic stroke, intracranial hemorrhage (ICH), major extracranial bleeding including major gastrointestinal bleeding, and mortality in patients with nonvalvular AF who initiated dabigatran or rivaroxaban treatment for stroke prevention. Design, Setting, and Participants:Retrospective new-user cohort study of 118 891 patients with nonvalvular AF who were 65 years or older, enrolled in fee-for-service Medicare, and who initiated treatment with dabigatran or rivaroxaban from November 4, 2011, through June 30, 2014. Differences in baseline characteristics were adjusted using stabilized inverse probability of treatment weights based on propensity scores. The data analysis was performed from May 7, 2015, through June 30, 2016. Exposures:Dabigatran, 150 mg, twice daily; rivaroxaban, 20 mg, once daily. Main Outcomes and Measures:Adjusted hazard ratios (HRs) for the primary outcomes of thromboembolic stroke, ICH, major extracranial bleeding including major gastrointestinal bleeding, and mortality, with dabigatran as reference. Adjusted incidence rate differences (AIRDs) were also estimated. Results:A total of 52 240 dabigatran-treated and 66 651 rivaroxaban-treated patients (47% female) contributed 15 524 and 20 199 person-years of on-treatment follow-up, respectively, during which 2537 primary outcome events occurred. Rivaroxaban use was associated with a statistically nonsignificant reduction in thromboembolic stroke (HR, 0.81; 95% CI, 0.65-1.01; P = .07; AIRD = 1.8 fewer cases/1000 person-years), statistically significant increases in ICH (HR, 1.65; 95% CI, 1.20-2.26; P = .002; AIRD = 2.3 excess cases/1000 person-years) and major extracranial bleeding (HR, 1.48; 95% CI, 1.32-1.67; P < .001; AIRD = 13.0 excess cases/1000 person-years), including major gastrointestinal bleeding (HR, 1.40; 95% CI, 1.23-1.59; P < .001; AIRD = 9.4 excess cases/1000 person-years), and with a statistically nonsignificant increase in mortality (HR, 1.15; 95% CI, 1.00-1.32; P = .051; AIRD = 3.1 excess cases/1000 person-years). In patients 75 years or older or with CHADS2 score greater than 2, rivaroxaban use was associated with significantly increased mortality compared with dabigatran use. The excess rate of ICH with rivaroxaban use exceeded its reduced rate of thromboembolic stroke. Conclusions and Relevance:Treatment with rivaroxaban 20 mg once daily was associated with statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily.
    背景与目标:
  • 【达比加群增强房颤患者的血小板反应性和血小板凝血酶受体表达: 评论。】 复制标题 收藏 收藏
    DOI:10.1111/jth.13705 复制DOI
    作者列表:Bonello L,Laine M,Camoin-Jau L,Frere C
    BACKGROUND & AIMS: -2
    背景与目标: -2
  • 【达比加群酯可减少实验性缺血性中风中凝血酶诱导的炎症和血栓形成。】 复制标题 收藏 收藏
    DOI:10.2174/1567202613666160517122605 复制DOI
    作者列表:Dittmeier M,Wassmuth K,Schuhmann MK,Kraft P,Kleinschnitz C,Fluri F
    BACKGROUND & AIMS: :Dabigatran etexilate (DE), a direct-acting, oral inhibitor of thrombin, significantly reduces the risk of stroke compared with traditional anticoagulants, without increasing the risk of major bleeding. However, studies on the fate of cerebral tissue after ischemic stroke in patients receiving DE are sparse and the role of dabigatran-mediated reduction of thrombin in this context has not yet been investigated. Here, we investigated whether pretreatment with DE reduces thrombin-mediated pro-inflammatory mechanisms and leakage of the blood-brain barrier (BBB) following ischemic stroke in rats. Male Wistar rats received DE (15 mg/kg) or a vehicle solution 1 hour before transient middle cerebral artery occlusion (tMCAO) for 90 minutes. Infarct volume, neurologic outcome and intracranial hemorrhage (ICH) were determined after tMCAO. Thrombin generation was indirectly assessed by measuring thrombin/antithrombin III complex. Microvascular patency was evaluated histologically. Cytokine expression and immunoreactivity of cluster of differentiation (CD) 68 were examined to characterize inflammatory processes after pretreatment with DE. BBB integrity was examined by quantifying brain edema. Rats given DE revealed a significant reduction in infarct size without an increase in ICH and significant recovery of neurologic deficits compared to controls. Administration of DE decreased thrombin generation and thrombus formation, dampened the CD68-immunoreactivity and attenuated pro-inflammatory cytokine expression in the cerebral parenchyma ipsilateral to the ischemic lesion. BBB permeability was unaltered following treatment with DE. In summary, prophylactic anticoagulation with DE improves stroke outcome by reducing thrombin-induced inflammation and thrombus formation without increasing the rate of ICH.
    背景与目标: : 达比加群酯 (DE) 是一种直接作用的口服凝血酶抑制剂,与传统抗凝剂相比,可显着降低中风的风险,而不会增加大出血的风险。然而,关于接受DE的缺血性卒中患者脑组织命运的研究很少,达比加群介导的凝血酶减少在这种情况下的作用尚未得到研究。在这里,我们研究了DE预处理是否可以减少大鼠缺血性中风后凝血酶介导的促炎机制和血脑屏障 (BBB) 的泄漏。雄性Wistar大鼠在短暂性大脑中动脉闭塞 (tMCAO) 90分钟前1小时接受DE (15 mg/kg) 或赋形溶液。tMCAO后确定梗塞体积,神经系统结果和颅内出血 (ICH)。通过测量凝血酶/抗凝血酶III复合物间接评估凝血酶的产生。组织学评估微血管通畅性。检查了细胞因子表达和分化簇 (CD) 68的免疫反应性,以表征用DE预处理后的炎症过程。通过量化脑水肿来检查BBB完整性。与对照组相比,给予DE的大鼠显示梗死面积显着减少,而ICH却没有增加,神经功能缺损也明显恢复。施用DE可减少凝血酶的产生和血栓形成,抑制CD68-immunoreactivity并减弱缺血性病变同侧脑实质中促炎性细胞因子的表达。用DE处理后,BBB渗透性没有改变。总之,DE预防性抗凝可通过减少凝血酶诱导的炎症和血栓形成而不增加ICH的发生率来改善卒中结局。
  • 【口服直接凝血酶抑制剂达比加群酯的临床药代动力学和药效学。】 复制标题 收藏 收藏
    DOI:10.2165/00003088-200847050-00001 复制DOI
    作者列表:Stangier J
    BACKGROUND & AIMS: :The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for the prophylaxis and treatment of thromboembolic disorders, with three trials completed in primary venous thromboembolism (VTE) prevention. Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran. Dabigatran has been shown to specifically and reversibly inhibit thrombin, the key enzyme in the coagulation cascade. Studies in healthy volunteers and in patients undergoing orthopaedic surgery have indicated that dabigatran has a predictable pharmacokinetic/pharmacodynamic profile, allowing for a fixed-dose regimen. Peak plasma concentrations of dabigatran are reached approximately 2 hours after oral administration in healthy volunteers, with no unexpected accumulation of drug concentrations upon multiple dosing. Excretion is predominantly via the renal route as unchanged drug. Dabigatran is not metabolized by cytochrome P450 isoenzymes. The small differences in dabigatran pharmacokinetics associated with age and gender are attributed to variations in renal function. Additional studies have shown that the pharmacokinetic/pharmacodynamic profile of dabigatran is consistent across a range of patient populations, with no effect of moderate hepatic impairment being observed. Drug-drug interactions are not observed with concomitant administration of atorvastatin, diclofenac or digoxin. The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding. Further phase III studies are ongoing, including acute VTE treatment and stroke prevention in atrial fibrillation; the results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.
    背景与目标: : 直接凝血酶抑制剂达比加群酯目前处于预防和治疗血栓栓塞性疾病的III期开发阶段,完成了预防原发性静脉血栓栓塞 (VTE) 的三项试验。达比加群酯是一种口服前药,可迅速吸收并转化为活性形式达比加群。达比加群已被证明可以特异性和可逆地抑制凝血酶,凝血酶是凝血级联反应中的关键酶。在健康志愿者和接受骨科手术的患者中进行的研究表明,达比加群具有可预测的药代动力学/药效学特征,可以采用固定剂量的方案。在健康志愿者中,口服给药后约2小时达到达比加群的血浆峰值浓度,多次给药后没有意外的药物浓度积累。排泄主要通过肾脏途径作为未改变的药物。达比加群不被细胞色素P450同工酶代谢。与年龄和性别相关的达比加群药代动力学的微小差异归因于肾功能的变化。其他研究表明,达比加群的药代动力学/药效学特征在一系列患者人群中是一致的,没有观察到中度肝损害的影响。阿托伐他汀,双氯芬酸或地高辛的同时给药未观察到药物相互作用。达比加群的药效学特征表明,抗凝有效,出血风险低。进一步的III期研究正在进行中,包括房颤的急性VTE治疗和中风预防; 到目前为止获得的结果表明,达比加群酯具有良好的耐受性,并且在治疗和预防血栓栓塞事件方面有效。
  • 【idarucizumab逆转颅内出血的达比加群: 文献的系统综述。】 复制标题 收藏 收藏
    DOI:10.1016/j.clineuro.2019.04.013 复制DOI
    作者列表:Lu VM,Phan K,Rao PJ,Sharma SV,Kasper EM
    BACKGROUND & AIMS: :Idarucizumab is the first Food and Drugs Administration (FDA) approved reversal agent for anticoagulant dabigatran, a direct thrombin inhibitor. Emerging evidence suggests idarucizumab can improve clinical outcome following dabigatran-associated hemorrhage, however, its specific use in intracranial hemorrhage has been poorly described. The aim of this study was to systematically review the available literature of idarucizumab in the setting of dabigatran-associated ICH to evaluate its efficacy in the stabilizing/resolving of the primary hemorrhage. A systematic search of 7 electronic databases from their earliest records to August 2018 was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. There were 864 articles identified for screening against selection criteria. The search identified 9 articles to be included in our analysis, describing hemorrhage outcomes in 23 dabigatran-associated cases of ICH managed by idarucizumab. Mean overall age was 76.2 years, with 43% females, and bleeding was subdural, subarachnoid and intracerebral in 43%, 13% and 43% cases respectively. Surgical intervention was pursued in 48% of cases. During the course of the hospitalization, the hemorrhages stabilized/resolved in 87% of patients, and worsened in 13%. In-hospital complications occurred in 4% of cases, and mortality occurred in 4% of cases as well. The available literature suggests that idarucizumab can be applied in the setting of ICH, for its therapeutic effect in patients presenting with dabigatran-associated ICH appears acceptable with no compromise to clinical safety. However, currently there is a paucity of data about various aspects that are involved in other aspects of ICH treatment, including recovery, that limits the significance of the current literature. As more evidence is published relating specifically to long-term ICH outcomes that have been treated by idarucizumab, we will be better placed to establish the optimal role of idarucizumab in the setting of dabigatran-associated ICH.
    背景与目标: : Idarucizumab是第一个食品和药物管理局 (FDA) 批准的抗凝剂达比加群 (一种直接凝血酶抑制剂) 逆转剂。新的证据表明,idarucizumab可以改善达比加群相关出血后的临床结局,然而,其在颅内出血中的具体应用还没有得到很好的描述。这项研究的目的是系统地回顾idarucizumab在达比加群相关ICH的背景下的可用文献,以评估其在稳定/解决原发性出血中的功效。按照系统评价和荟萃分析 (PRISMA) 指南的首选报告项目,对7个电子数据库从最早记录到2018年8月进行了系统搜索。有864篇文章被确定用于根据选择标准进行筛选。搜索确定了9篇文章纳入我们的分析,描述了由idarucizumab管理的23例达比加群相关ICH病例的出血结果。平均年龄76.2岁,女性43% 例,硬膜下、蛛网膜下腔和脑内出血分别为43% 例、13% 例和43% 例。在48% 病例中进行了手术干预。在住院期间,87% 患者出血稳定/缓解,13% 恶化。4% 病例发生院内并发症,4% 病例也发生死亡率。现有文献表明,idarucizumab可用于ICH的治疗,因为其在出现达比加群相关ICH的患者中的治疗效果似乎可以接受,而不会损害临床安全性。但是,目前缺乏有关ICH治疗其他方面 (包括恢复) 的各个方面的数据,这限制了当前文献的重要性。随着更多的证据被公布,特别是与经过idarucizumab治疗的长期ICH结局有关,我们将更好地确定idarucizumab在dabigatran相关ICH中的最佳作用。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录